PMID- 12864774
OWN - NLM
STAT- MEDLINE
DCOM- 20030917
LR  - 20190827
IS  - 0014-2972 (Print)
IS  - 0014-2972 (Linking)
VI  - 33
IP  - 8
DP  - 2003 Aug
TI  - Metalloproteinases 2 and 9 are increased in plasma of patients with heart 
      failure.
PG  - 648-56
AB  - BACKGROUND: Progression of heart failure is associated with interstitial changes 
      in the heart and in areas distant from the heart. Enhanced expression of 
      metalloproteinases 2 and 9 and of metalloproteinases tissue inhibitors 1 and 2 
      have been found in ventricular tissue of patients with heart failure. Our aim was 
      to determine whether increased activity of metalloproteinase-2, 
      metalloproteinase-9 and of metalloproteinases tissue inhibitor-1 and 
      metalloproteinases tissue inhibitor-2 were also present in plasma of patients 
      with heart failure. DESIGN: Levels of metalloproteinase-2, metalloproteinase-9 
      and of metalloproteinase tissue inhibitor-1 and metalloproteinases tissue 
      inhibitor-2 were measured in venous blood of 51 patients with heart failure, and 
      were compared with levels of 52 control subjects. Samples collected from patients 
      and control subjects were assayed for gelatinolytic activity (zymography) and for 
      protein levels. RESULTS: Compared with the control subjects, the patients with 
      heart failure had a significant increase in activity levels (mean +/- SE, ng 
      mL(-1)) of prometalloproteinase-9 (95.1+/-11.2 and 38.9+/-4.5*), activ. 
      metalloproteinase-9 (18.4+/-2.5 and 10.9+/-1.3*), and of prometalloproteinase-2 
      (571.4+/-26.1 and 456.8+/-21.1*) (respectively: patients and control subjects; 
      *P<0.05). Metalloproteinases tissue inhibitor-1, but not metalloproteinases 
      tissue inhibitor-2 protein values were higher in the patients. Among the 
      patients, clinical status and New York Heart Association (NYHA) class did not 
      correlate with the metalloproteinase concentrations. Positive correlations with 
      left ventricular volumes, and negative correlations with lipid values were 
      obtained for prometalloproteinase-2; positive correlations with total number of 
      white cells and neutrophils were obtained for prometalloproteinase-9; and 
      positive correlations with lactate dehydrogenase, serum fibrinogen, aspartate 
      transaminases were found for activ. metalloproteinase-9. CONCLUSIONS: Regardless 
      of the clinical phase of heart failure, elevated levels of activity and of 
      circulating metalloproteinase protein levels suggest the presence of persistent 
      extracellular remodeling in patients with heart failure.
FAU - Altieri, P
AU  - Altieri P
AD  - Department of Internal Medicine, University of Genova, Genova, Italy.
FAU - Brunelli, C
AU  - Brunelli C
FAU - Garibaldi, S
AU  - Garibaldi S
FAU - Nicolino, A
AU  - Nicolino A
FAU - Ubaldi, S
AU  - Ubaldi S
FAU - Spallarossa, P
AU  - Spallarossa P
FAU - Olivotti, L
AU  - Olivotti L
FAU - Rossettin, P
AU  - Rossettin P
FAU - Barsotti, A
AU  - Barsotti A
FAU - Ghigliotti, G
AU  - Ghigliotti G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur J Clin Invest
JT  - European journal of clinical investigation
JID - 0245331
RN  - 0 (Protease Inhibitors)
RN  - 0 (Tissue Inhibitor of Metalloproteinase-1)
RN  - 0 (Tissue Inhibitor of Metalloproteinases)
RN  - 127497-59-0 (Tissue Inhibitor of Metalloproteinase-2)
RN  - EC 3.4.24.24 (Matrix Metalloproteinase 2)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
SB  - IM
MH  - Aged
MH  - Cardiac Output, Low/*blood
MH  - Enzyme-Linked Immunosorbent Assay/methods
MH  - Extracellular Matrix/metabolism
MH  - Humans
MH  - Male
MH  - Matrix Metalloproteinase 2/*blood
MH  - Matrix Metalloproteinase 9/*blood
MH  - Middle Aged
MH  - Protease Inhibitors/blood
MH  - Tissue Inhibitor of Metalloproteinase-1/blood
MH  - Tissue Inhibitor of Metalloproteinase-2/blood
MH  - Tissue Inhibitor of Metalloproteinases/blood
EDAT- 2003/07/17 05:00
MHDA- 2003/09/18 05:00
CRDT- 2003/07/17 05:00
PHST- 2003/07/17 05:00 [pubmed]
PHST- 2003/09/18 05:00 [medline]
PHST- 2003/07/17 05:00 [entrez]
AID - 1187 [pii]
AID - 10.1046/j.1365-2362.2003.01187.x [doi]
PST - ppublish
SO  - Eur J Clin Invest. 2003 Aug;33(8):648-56. doi: 10.1046/j.1365-2362.2003.01187.x.